Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Sarcoma 204Osteosarcoma 76Sarcoma, Ewing 51Rhabdomyosarcoma 49Melanoma 43Neuroblastoma 38Gastrointestinal Stromal Tumors 35Neoplasms 34Neoplasm Metastasis 32Colorectal Neoplasms 32Bone Neoplasms 32Glioblastoma 29Breast Neoplasms 26Ovarian Neoplasms 25Glioma 24Wilms Tumor 23Rhabdoid Tumor 23Gliosarcoma 23Carcinoma, Non-Small-Cell Lung 23Liposarcoma 22Lymphoma, Non-Hodgkin 21Sarcoma, Kaposi 20Neurofibrosarcoma 20Carcinoma, Renal Cell 20Pancreatic Neoplasms 19Medulloblastoma 19Hepatoblastoma 19Lymphoma 18Desmoid Tumors 18Thyroid Neoplasms 17

Interventions

enasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal undifferentiated carcinoma × Sarcoma × 90 days × Clear all
NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡